Yuji Tomizawa¹, Friedemann Paul², Eoin P. Flanagan³, Tania Kumpfel⁴, Romain Marignier⁵, Kazuo Fujihara⁶, Cheryl Hemingway⁷, Ivana Vodopivec⁸, Daniela Stokmaier⁸, Kristina Weber⁸, Michael Levy⁹ (1.Juntendo University, School of Medicine, Department of Neurology, Japan, 2.Charite-Universitatsmedizin Berlin, Germany, 3.Mayo Clinic, USA, 4.Institute of Clinical Neuroimmunology, University Hospital, LMU, Munich, Germany, 5.The University Hospital of Lyon, France, 6.Department of Multiple Sclerosis Therapeutics, Fukushima Medical University, School of Medicine, Japan, 7.GOSH and ICH, London, UK, 8.Roche, Switzerland, 9.MGH, USA)

Dewei She¹, John W. Lindsey², Evanthia Bernitsas³, Naruyasu Komorita⁴, Bruce A C. Cree⁵ (1.Horizon Therapeutics, USA, 2.Division of Multiple Sclerosis and Neuroimmunology, University of Texas Health Science Center at Houston, USA, 3.Multiple Sclerosis Center, Wayne State School of Medicine, USA, 4.Mitsubishi Tanabe Pharma Corporation, Japan, 5.UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, USA)

Hideto Nakajima¹, Hesham Abboud², Sarosh R. Irani³, Soon-tae Lee⁴, Amanda Piquet⁵, Sean J. Pittock⁶, Ann E. Yeh⁷, James Overell⁸, Sharmila Rajan⁹, Muna El-khairi¹⁰, Jeffrey M. Gelfand¹¹ (1.Nihon University, Neurology, Japan, 2.UH Cleveland Medical Center, USA, 3.NDCN, Oxford University, UK, 4.Seoul National University Hospital, Korea, 5.University of Colorado, USA, 6.Mayo Clinic, USA, 7.SickKids, University of Toronto, Canada, 8.F. Hoffmann-La Roche Ltd., Switzerland, 9.Genentech, Inc., USA, 10.Roche Products Ltd., UK, 11.UCSF, USA)

Yuki Yokota, Satoshi Hirose, Makoto Hara, Hideto Nakajima (Division of Neurology, Department of Medicine, Nihon University School of Medicine, Japan)